ARAY
Accuray Inc

2,362
Mkt Cap
$174.72M
Volume
574,907.00
52W High
$2.95
52W Low
$1.14
PE Ratio
-89.60
ARAY Fundamentals
Price
$1.50
Prev Close
$1.55
Open
$1.58
50D MA
$1.63
Beta
1.60
Avg. Volume
736,851.33
EPS (Annual)
-$0.0155
P/B
2.15
Rev/Employee
$463,136.36
Loading...
Loading...
News
all
press releases
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025
Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025 Accuray to Report First Quarter Fiscal 2026 Financial Results on November 5, 2025 PR Newswire MADISON, Wis., Oct. 28...
PR Newswire·7h ago
News Placeholder
More News
News Placeholder
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY sees strong order momentum, APAC growth and CyberKnife demand, but soft product sales and regional headwinds cloud near-term gains.
Zacks·1mo ago
News Placeholder
Accuray Stock Down as Q4 Earnings Miss Estimates, Revenues Down Y/Y
ARAY stock down after Q4 earnings miss estimates, with product sales hit by tariffs and regional demand softness.
Zacks·3mo ago
News Placeholder
Accuray (ARAY) Reports Break-Even Earnings for Q4
Accuray (ARAY) delivered earnings and revenue surprises of -100.00% and +2.49%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
NeuroPace, Inc. (NPCE) Reports Q2 Loss, Beats Revenue Estimates
NeuroPace (NPCE) delivered earnings and revenue surprises of -8.33% and +0.75%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Astrana Health, Inc. (ASTH) Q2 Earnings Lag Estimates
Astrana Health, Inc. (ASTH) delivered earnings and revenue surprises of -47.22% and +2.31%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
OrthoPediatrics (KIDS) Reports Q2 Loss, Misses Revenue Estimates
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +35.29% and -1.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
ARAY rides strong global demand and CyberKnife momentum, but order declines and backlog pressure temper the outlook.
Zacks·3mo ago
News Placeholder
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
Zacks·4mo ago
News Placeholder
Why Is Accuray (ARAY) Up 17% Since Last Earnings Report?
Zacks·5mo ago

Latest ARAY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.